Formulation and evaluation of amphotericin B emulsion gel against Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling
Parasitology Research · 2026
DOI: 10.1007/s00436-026-08626-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parasitology Research, 2026. Verfasst von Nazgol Safavi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Science, Kerman, Iran. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Cutaneous, Leishmania major, Antiprotozoal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cutaneous leishmaniasis (CL) is the most prevalent form, with increasing incidence linked to factors such as drug resistance, HIV co-infection, and lack of effective vaccines. Amphotericin B (AmB) is an effective antileishmanial drug; however, its clinical use is limited by nephrotoxicity, high cost, and the requirement for parenteral administration. Therefore, there is a need for safer, non-invasive topical formulations with improved efficacy and reduced systemic toxicity. This study aimed to develop and evaluate a novel Amphotericin B-loaded nanoemulsion gel (AmB-NEG) for the topical treatment of Leishmania major infection in mice. AmB was incorporated into a Carbomer 940-based nanoemulsion gel, and its physicochemical properties, including pH, stability, and particle size, were characterized. In vivo efficacy was assessed in BALB/c mice infected with L. major. Lesion size, splenic parasite burden (by qPCR), histopathological changes, and cytokine gene expression (IFN-γ, IL-12, IL-4, and IL-10) were evaluated. The optimized AmB-NEG exhibited uniform nanodroplets (< 50 nm), excellent stability, and a near-neutral pH suitable for dermal application. Topical AmB-NEG significantly reduced lesion size and splenic parasite burden compared with both untreated and conventional AmB-treated groups (P < 0.01). Histopathological analysis revealed reduced inflammation and parasite density, while qRT-PCR confirmed upregulation of Th1 cytokines (IFN-γ, IL-12) and downregulation of Th2 cytokines (IL-4, IL-10). The developed AmB-NEG demonstrated enhanced therapeutic efficacy and immunomodulatory activity against cutaneous leishmaniasis while minimizing systemic toxicity. This topical nanoformulation offers a promising, patient-friendly alternative to conventional AmB therapy and warrants further preclinical and clinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Science, Kerman, Iran.
- Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Pathology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
- Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran. fatemeh7267@gmail.com.
Zitieren
APA
Safavi, N., Ohadi, M., Dehghannoudeh, G., Sharifi, I., Salarkia, E., Dabiri, S., & Sharifi, F. (2026). Formulation and evaluation of amphotericin B emulsion gel against Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling. Parasitology Research. https://doi.org/10.1007/s00436-026-08626-0
Vancouver
Safavi N, Ohadi M, Dehghannoudeh G, Sharifi I, Salarkia E, Dabiri S, et al. Formulation and evaluation of amphotericin B emulsion gel against Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling. Parasitology Research. 2026. doi:10.1007/s00436-026-08626-0
BibTeX
@article{Safavi2026,
author = {Safavi, Nazgol and Ohadi, Mandana and Dehghannoudeh, Gholamreza and Sharifi, Iraj and Salarkia, Ehsan and Dabiri, Shahriar and Sharifi, Fatemeh},
title = {Formulation and evaluation of amphotericin B emulsion gel against Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling},
journal = {Parasitology Research},
year = {2026},
doi = {10.1007/s00436-026-08626-0}
}
EUVIMED